Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rachel Tellez

Optometrist San Antonio, TX Doctor of Optometry

NPI 1720040231 CMS profile 1124214

24165 Ih 10 W, Ste 229, San Antonio, TX 78257

Open in the dashboard

General payments

$4,167

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rachel Tellez of San Antonio, TX is reported in the CMS Open Payments database as having received $4,167 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,080 8
2024 General $615 15
2023 General $1,865 11
2022 General $395 11
2021 General $71 4
2020 General $86 3
2019 General $56 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rachel Tellez
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Rachel Tellez were reported at $1,080. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Rachel Tellez Optometrist median Middle half National median
2019 $56 $159 $67–$371 $163
2020 $86 $72 $29–$165 $114
2021 $71 $125 $46–$292 $132
2022 $395 $162 $66–$374 $149
2023 $1,865 $177 $72–$406 $160
2024 $615 $188 $77–$427 $164
2025 $1,080 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Marco Ophthalmic, Inc. $1,500 1 payment
  2. Bausch & Lomb Americas Inc. $895 22 payments
  3. Lumenis BE inc $849 1 payment
  4. Alcon Vision LLC $509 15 payments
  5. CooperVision Inc. $180 6 payments
  6. Johnson & Johnson Surgical Vision, Inc. $70 2 payments
  7. Sun Pharmaceutical Industries Inc. $48 2 payments
  8. ABB Con-Cise Optical Group LLC $34 1 payment
  9. Bausch & Lomb, a division of Bausch Health US, LLC $23 1 payment
  10. AbbVie, Inc. $21 1 payment
  11. Other $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,648 52 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 1 payment
  3. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. OPD-III $1,500 1 payment
  2. M22 $849 1 payment
  3. INFUSE $693 21 payments
  4. TOTAL30 $291 8 payments
  5. BIOTRUE ONE DAY $197 11 payments
  6. Precision7 $169 4 payments
  7. BIOTRUE $125 1 payment
  8. ULTRA MULTIFOCAL TORIC $125 1 payment
  9. MyDay Contact Lens $120 3 payments
  10. VYZULTA $100 1 payment
  11. Other $489 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Optometry: 120

Drug cost

$162

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 15 $162

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$11,176

Medicare's payments for the services billed

Medicare patients

156

Average age 76

Services billed

180

95 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 48%
Ischemic heart disease 30%
Osteoporosis 24%
Chronic kidney disease 22%
Diabetes 21%
Cancer 14%
Heart failure 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record